Gastrointestinal diseases market

1

Gastrointestinal Diseases Market, by Drug Category, and Geography – Global Opportunity Analysis and Industry

Forecast, 2014 – 2022

October 2016

2

Table of Contents

1 Market Overview ..................................................................................................................... 11

1.1 Definitions ....................................................................................................................... 11

1.2 Research Methodology .................................................................................................... 11

1.3 Market Segmentation ...................................................................................................... 12

2 Executive Summary ................................................................................................................. 14

2.1 Market Summary: Global Gastrointestinal Diseases Market ............................................. 14

2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs.

2022) ................................................................................................................................. 15

2.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs.

2021) ................................................................................................................................. 15

3 Market Dynamics ..................................................................................................................... 17

3.1 Drivers ............................................................................................................................. 17

3.2 Restraints ......................................................................................................................... 17

3.3 Opportunities ................................................................................................................... 17

3.4 Premium Industry Trends ................................................................................................. 18

4 Industry Analysis ...................................................................................................................... 19

4.1 Major Selling Drug Analysis .............................................................................................. 19

4.1.1 Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis

(2015) ................................................................................................................................. 19

4.1.2 Nexium ..................................................................................................................... 19

4.1.3 Losec/Prilosec .......................................................................................................... 20

4.1.4 Dexilant .................................................................................................................... 20

4.1.5 Lialda ........................................................................................................................ 20

4.1.6 Entyvio ..................................................................................................................... 20

4.1.7 Emend ...................................................................................................................... 21

4.1.8 Creon ....................................................................................................................... 21

4.2 Pipeline Analysis .............................................................................................................. 22

4.2.1 Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis

(2014 – 2022) .......................................................................................................................... 22

4.2.2 BEKINDA (RHB-104) .................................................................................................. 23

4.2.3 RHB-105 (H. pylori) ................................................................................................... 23

SAMPLE

3

4.2.4 RHB 104 (GI/Inflammation) ...................................................................................... 23

4.2.5 Relamorelin .............................................................................................................. 23

4.2.6 Viberzi ...................................................................................................................... 24

4.2.7 mAbs Stelara (ustekinumab) ..................................................................................... 24

4.2.8 AMG-714 .................................................................................................................. 24

4.3 Key event analysis ............................................................................................................ 25

5 Global Gastrointestinal Diseases Market, by Drug Category ..................................................... 26

5.1 Overview.......................................................................................................................... 26

5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022. 27

5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$

million), By Drug Category (2014 – 2022) ................................................................................. 27

5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –

2022) ................................................................................................................................. 27

5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 &

2022 ................................................................................................................................. 28

5.2 Antacid & Anti-Ulcerant ................................................................................................... 29

5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) . 29

5.3 GIT Anti-inflammatory ...................................................................................................... 29

5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) .... 29

5.4 Antiemetic ....................................................................................................................... 30

5.4.1 Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ..................... 30

5.5 Anti-diarrhoea .................................................................................................................. 30

5.5.1 Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022) ................ 30

5.6 Other GIT Therapeutics .................................................................................................... 31

5.6.1 Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) .. 31

6 Global Gastrointestinal Diseases Market, by Geography .......................................................... 32

6.1 Overview.......................................................................................................................... 32

6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021 ...... 32

6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 –

2022) ................................................................................................................................. 33

6.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 &

2022 ................................................................................................................................. 33

6.2 North America.................................................................................................................. 34

SAMPLE

4

6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021 ..

................................................................................................................................. 34

6.2.2 North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014

– 2022) ................................................................................................................................. 35

6.2.3 North America Gastrointestinal Diseases Market Size (US$ million), By Country, 2016

& 2021 ................................................................................................................................. 35

6.2.3.1 U.S. ....................................................................................................................... 35

6.2.3.1.1 Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y

Growth (%) ....................................................................................................................... 35

6.2.3.2 Canada ................................................................................................................. 36

6.2.3.2.1 Gastrointestinal Diseases Market in Canada, Market Size (US$ million) and Y-o-Y

Growth (%) ....................................................................................................................... 36

6.2.4 North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category

(2014 – 2022) .......................................................................................................................... 36

6.3 Europe ............................................................................................................................. 37

6.3.1 Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37

6.3.2 Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) .

................................................................................................................................. 37

6.3.3 Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 .

................................................................................................................................. 38

6.3.3.1 Germany............................................................................................................... 38

6.3.3.1.1 Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y-

o-Y Growth (%) ................................................................................................................. 38

6.3.3.2 France .................................................................................................................. 39

6.3.3.2.1 Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y

Growth (%) ....................................................................................................................... 39

6.3.3.3 Rest of the Europe ................................................................................................ 39

6.3.3.3.1 Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$

million) and Y-o-Y Growth (%) .......................................................................................... 39

6.3.4 Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –

2022) ................................................................................................................................. 39

6.4 Asia-Pacific ....................................................................................................................... 40

6.4.1 Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ... 40

6.4.2 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 –

2022) ................................................................................................................................. 41

SAMPLE

5

6.4.3 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 &

2022 ................................................................................................................................. 41

6.4.3.1 India ..................................................................................................................... 41

6.4.3.1.1 Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y

Growth (%) ....................................................................................................................... 41

6.4.3.2 China .................................................................................................................... 42

6.4.3.2.1 Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y

Growth (%) ....................................................................................................................... 42

6.4.3.3 Rest of the Asia-Pacific.......................................................................................... 42

6.4.3.3.1 Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$


6.4.4 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category

(2014 – 2022) .......................................................................................................................... 42

6.5 Rest of the World ............................................................................................................. 43

6.5.1 Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 &

2021 ................................................................................................................................. 43

6.5.2 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country

(2014 – 2022) .......................................................................................................................... 44

6.5.3 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country,

2016 & 2021 ............................................................................................................................ 44

6.5.3.1 Latin America........................................................................................................ 44

6.5.3.1.1 Gastrointestinal Diseases Market in Latin America, Market Size (US$ million)

and Y-o-Y Growth (%) ....................................................................................................... 44

6.5.3.2 Middle East and Africa .......................................................................................... 45

6.5.3.2.1 Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$


6.5.4 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug

Category (2014 – 2022) ............................................................................................................ 45

7 Competitive Landscape ............................................................................................................ 46

7.1 Market Share Analysis ...................................................................................................... 46

7.2 Key Innovators ................................................................................................................. 46

7.2.1 RedHill ...................................................................................................................... 46

7.2.2 Allergan .................................................................................................................... 47

7.2.3 Shire ......................................................................................................................... 47

8 Company Profiles ..................................................................................................................... 48

SAMPLE

6

8.1 AstraZeneca ..................................................................................................................... 48

8.1.1 Overview .................................................................................................................. 48

8.1.2 Key Strategies ........................................................................................................... 48

8.1.2.1 Strong research and development activities ......................................................... 48

8.1.2.2 Novel therapeutics in company’s product offering ................................................ 48

8.1.3 Recent Developments .............................................................................................. 49

8.2 Valeant (Salix Pharmaceuticals) ........................................................................................ 50

8.2.1 Overview .................................................................................................................. 50

8.2.2 Key Strategies ........................................................................................................... 50

8.2.2.1 Strategic merger and acquisitions ......................................................................... 50

8.2.2.2 US FDA approvals ................................................................................................. 50

8.2.2.3 Strong positioning in gastrointestinal anti-inflammatory therapeutic segment ..... 51


8.3 Takeda Pharmaceutical Company Limited ........................................................................ 52

8.3.1 Overview .................................................................................................................. 52

8.3.2 Key Strategies ........................................................................................................... 52

8.3.2.1 Conducting awareness programs .......................................................................... 52

8.3.2.2 US FDA approval ................................................................................................... 52

8.3.2.3 Expansion of product portfolio through acquisitions ............................................. 53

8.3.2.4 Focus on core geography markets......................................................................... 53


8.4 Shire ................................................................................................................................ 54

8.4.1 Overview .................................................................................................................. 54

8.4.2 Key Strategy ............................................................................................................. 54

8.4.2.1 Expansion through strategic acquisition ................................................................ 54

8.4.2.2 Focus on the development of therapeutics for rare diseases................................. 54

8.4.2.3 Expansion of product portfolio through innovation ............................................... 54


8.5 Johnson & Johnson Private Limited .................................................................................. 56

8.5.1 Overview .................................................................................................................. 56

8.5.2 Key Strategy ............................................................................................................. 56

SAMPLE

7

8.5.2.1 Focus on product development and regulatory approvals ..................................... 56


8.6 Eisai Co., Ltd. .................................................................................................................... 58

8.6.1 Overview .................................................................................................................. 58

8.6.2 Key Strategy ............................................................................................................. 58

8.6.2.1 Pricing strategy to emphasize affordability ........................................................... 58

8.6.2.2 Focus on emerging market.................................................................................... 58

8.6.2.3 Transformation of product portfolio ..................................................................... 58


8.7 Allergan ........................................................................................................................... 60

8.7.1 Overview .................................................................................................................. 60

8.7.2 Key Strategies ........................................................................................................... 60

8.7.2.1 Strategic merger and acquisitions ......................................................................... 60


9 Scalar 360 Degree Market Perspective ..................................................................................... 61

9.1 Global Gastrointestinal Diseases Market Trend ................................................................ 61

10 Appendix ................................................................................................................................. 62

10.1 Acronyms ......................................................................................................................... 62

SAMPLE

8

List of Tables

Table 1. Definitions .................................................................................................................... 11

Table 2. Market Summary: Global Gastrointestinal Diseases Market.......................................... 14

Table 3. Global Gastrointestinal Diseases Market Drivers........................................................... 17

Table 4. Global Gastrointestinal Diseases Market Restraints ...................................................... 17

Table 5. Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis

(2015) .................................................................................................................................... 19

Table 6. Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis (2014

– 2022) .................................................................................................................................... 22

Table 7. Key event analysis- Global Gastrointestinal Diseases Market ........................................ 25

Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million),

By Drug Category (2014 – 2022) ...................................................................................................... 27

Table 9. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –

2022) .................................................................................................................................... 27

Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) ..... 29

Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022) ........ 29

Table 12. Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ......................... 30

Table 13. Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022) .................... 30

Table 14. Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) ...... 31

Table 15. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022) .

.................................................................................................................................... 33

Table 16. North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014 –

2022) .................................................................................................................................... 35

Table 17. Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y Growth (%)

.................................................................................................................................... 36

Table 18. Gastrointestinal Diseases Market in Rest of Canada, Market Size (US$ million) and Y-o-Y

Growth (%) .................................................................................................................................... 36

Table 19. North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category

(2014 – 2022) .................................................................................................................................. 36

Table 20. Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) 38

Table 21. Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y-o-Y

Growth (%) .................................................................................................................................... 38

Table 22. Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y Growth

(%) .................................................................................................................................... 39

SAMPLE

9

Table 23. Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Y-

o-Y Growth (%) ................................................................................................................................ 39

Table 24. Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –

2022) .................................................................................................................................... 39

Table 25. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 –

2022) .................................................................................................................................... 41

Table 26. Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y Growth

(%) .................................................................................................................................... 42

Table 27. Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y Growth

(%) 42

Table 28. Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$ million)

and Y-o-Y Growth (%) ...................................................................................................................... 42

Table 29. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014

– 2022) 42

Table 30. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country (2014

– 2022) 44

Table 31. Gastrointestinal Diseases Market in Latin America, Market Size (US$ million) and Y-o-Y

Growth (%) 45

Table 32. Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$ million)

and Y-o-Y Growth (%) ...................................................................................................................... 45

Table 33. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug Category

(2014 – 2022) .................................................................................................................................. 45

Table 34. AstraZeneca – Company Overview ............................................................................... 48

Table 35. Valeant – Company Overview ....................................................................................... 50

Table 36. Takeda Pharmaceutical Company Limited – Company Overview................................... 52

Table 37. Shire – Company Overview ........................................................................................... 54

Table 38. Johnson & Johnson Private Limited – Company Overview ............................................ 56

Table 39. Eisai Co., Ltd. – Company Overview .............................................................................. 58

Table 40. Allergan– Company Overview ....................................................................................... 60

Table 41. Global Gastrointestinal Diseases Market Trend ............................................................ 61

Table 42. List of Acronyms ........................................................................................................... 62

SAMPLE

10

List of Figures

Figure 1. Research Methodology................................................................................................. 12

Figure 2. Gastrointestinal Diseases Market, By Drug Category..................................................... 12

Figure 3. Gastrointestinal Diseases Market, By Geography .......................................................... 13

Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs.

2022) 15

Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs.

2021) 15

Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 .... 27

Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 &

2022 28

Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021 .......... 32

Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022

33

Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021

34

Figure 11. North America Gastrointestinal Diseases Market Size (US$ illion), By Country, 2016 &

2021 35

Figure 12. Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37

Figure 13. Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2022

38

Figure 14. Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ... 40

Figure 15. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 &

2022 41

Figure 16. Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 &

2021 43

Figure 17. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country,

2016 & 2021 44

Figure 18. Market Share Analysis of Key Players ........................................................................ 46

SAMPLE

11

1 Market Overview

1.1 Definitions

Table 1. Definitions

Segment Drugs

Antacid & Anti-Ulcerant Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid, Takepron,

Pentozol, Pariet/Aciphex, Carafate/Sulcrate, Cytotec, and Selbex

GIT Anti-inflammatory Lialda, Delzicol, Asacol, Pentasa, Uceris, Apriso, Entyvio, Simponi

/Simponi Aria, and Remicade

Antiemetic Agent Emend, Aloxi, Kytril and others

Anti-diarrhoea Agent Enterogermina, Smecta, Imodium, Bioflor, Seirogan A and others

Other GIT Therapeutics Creon, Donnatal, Daikenchuto, Bifico, Linzess (US)/Constella, and

others

Pipeline Drugs BEKINDA (RHB-102), RHB-105 (H. pylori), RHB 104, Relamorelin, Viberzi,

mAbs Stelara (ustekinumab) and AMG-714

Source: Scalar Market Research Analysis

1.2 Research Methodology

The research methodology for market research reports at Scalar Market Research

includes a combination of top-down and bottom-up research formats. Continuous

market tracking, rigorous fact-checking, data-triangulation, and multiple layers of

quality control ensure high quality data that can be leveraged for actionable insights.

The global market for gastrointestinal diseases involves the study of different

branded and generic gastrointestinal therapeutics. The 'Global Gastrointestinal

Diseases Market – Industry Analysis, Market Size and Forecast (2014–2022)' report

includes market size and forecast, estimated from the period 2016 to 2022. This

report encompasses a detailed study for various gastrointestinal therapeutic used for

the treatment of conditions such as ulcerative colitis, irritable bowel diseases, celiac

diseases, and many others.

Drug category segment is primarily categorized into Antacid & Anti-Ulcerant, GIT

Anti-inflammatory, Antiemetic Agent, Anti-diarrhoea Agent and Other GIT

Therapeutics. The market size and forecast for each drug category type has been

SAMPLE

12

provided for the period 2014 to 2022, considering 2014 and 2015 as the base year.

The report also provides the compounded annual growth rate and due to (% CAGR)

for the forecast period 2016 to 2022 for each drug category.

Based on Geography, the market is segmented as North America, Europe, Asia-

Pacific and Rest of the World (RoW). The market size and forecast for geography

has been estimated for the period 2014 to 2022 in terms of revenue (US$ million).

The report also estimates the compounded annual growth rate (CAGR %) during the

forecast period from 2016 to 2022 for all the geographies mentioned above.

Figure 1. Research Methodology


1.3 Market Segmentation

Figure 2. Gastrointestinal Diseases Market, By Drug Category


Global

Market

Size

Market-specific Revenues of Key Market

Players

Revenues of Key Market Players

Global Market

Size

Segment-specific Market Size

Regional

Market

Size

Bottom-up

Top-down

SAMPLE

13

Figure 3. Gastrointestinal Diseases Market, By Geography


SAMPLE

14

2 Executive Summary

The global gastrointestinal diseases market was estimated to be US$XX million in

2016. This market is expected to grow at a CAGR of XX% in the forecast period and

is expected to be US$XX billion in 2022. This report segments the global

gastrointestinal diseases market by drug category and geography.

2.1 Market Summary: Global Gastrointestinal Diseases Market

Table 2. Market Summary: Global Gastrointestinal Diseases Market

Factors 2016 2022

Global Gastrointestinal Diseases Market (US$ million)

17,271.2 14,859.7

Largest Revenue Generating Market, by Drug Category (US$ million)

Lowest Revenue Generating Market, by Drug Category (US$ million)

Segment with Highest Growth Rate, by Drug Category

Largest Revenue Generating Market, by Geography (US$ million)

Lowest Revenue Generating Market, by Geography (US$ million)

Segment with Highest Growth Rate, by Geography

Key Market Players (2015)

Pipeline Drugs

Source: Scalar Market Research analysis

SAMPLE

15

2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022)

Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs. 2022)

Source: Scalar Market Research analysis

Of the different drug category, antacid & anti-ulcerant accounted for the largest share

of the global market revenue. Growth of this segment is majorly attributed to the

approval of novel proton pump inhibitors by government regulatory. In addition,

growing demand for gastrointestinal therapeutics such as Nexium, Dexilant, and

Sulcrate in developing as developed countries drives the market growth of this

segment. However, anti-diarrohea segment recorded around 3.5% share of the

global market and is expected lose its market share during the forecast period owing

to the generic drug entry.

2.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2022)

Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs. 2022)

45.2%

26.7%

12.5%

3.6%

12.0%

2016

40.7%

38.6%

8.2%

2.4%10.1%

2022

Antacid & Anti-

Ulcerant

GIT Anti-inflamatory

Antiemetic

Agent

Anti-diarrhoea Agent

Other GIT Therapeutics

SAMPLE

17

3 Market Dynamics

3.1 Drivers

Table 3. Global Gastrointestinal Diseases Market Drivers

Drivers 2014-16 2017- 19 2020-22

● ● ● ◕ ◕ ● ◑ ● ● Source: Scalar Market Research Analysis

Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact

3.2 Restraints

Table 4. Global Gastrointestinal Diseases Market Restraints

Restraints 2014-16 2017- 19 2020-22

◑ ● ◕ ◕ ◑ ◑ Source: Scalar Market Research Analysis

Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact

3.3 Opportunities

Development of biologic therapeutics for the treatment of gastrointestinal

diseases due to its favorable safety profile

Development of monoclonal antibody related gastrointestinal therapeutics

Increasing investment in emerging market of Asia-Pacific

SAMPLE

18

3.4 Premium Industry Trends

Companies focusing on Irritable Bowel Diseases with Diarrhoea therapeutics

will serve as potential market to record high growth profit

SAMPLE

26

5 Global Gastrointestinal Diseases Market, by Drug Category

5.1 Overview

The global gastrointestinal diseases market is categorized into different types of drug

category such as Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic, Anti-

diarrhoea, and other GIT Therapeutics. This chapter analyzes the market revenue

generated by the different branded and generic therapeutics falls under different

drug categories. Antacid and Anti-Ulcerant section covers the study of variety of

Omeprazole drugs such as Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid,

Takepron, Pentozol, Pariet/Aciphex, and drugs such as Sucralfate

(Carafate/Sulcrate) , Cytotec and others. Companies such as AstraZeneca, Takeda

Pharmaceuticals and Daichi Sankyo are aggressively investing in research and

development activities to develop new anti-ulcerant moieties which help this segment

to grow during the forecast period. However, negative growth of the segment is

majorly attributed to the patent expiry of AstraZeneca’s two brand drug,

Losec/Prilosec and Nexium. On other side, the demand for Takeda Pharmaceutical’s

proton pump inhibitor (Dexilant) is increasing due to its unique mechanism of action

which is considered as positive impact for the growth of this segment.

GIT Anti-inflammatory comprises drugs such as Lialda, Delzicol, Asacol, Pentasa,

Uceris, Apriso, Entyvio, Remicade, and others. This segment is anticipated to growth

with the positive growth rate of XX% during the forecast year 2016 to 2022. The

growth of the segment is majorly supported by the launch of Takeda’s vedolizumab

category of drug (Entyvio). This monoclonal antibody based Anti-inflammatory drug

is expected to hit the market with highest growth rate due to its high efficacy for the

treatment of gastrointestinal diseases. Additionally, drug molecules such as Lialda

(Shire, Inc.) and Apriso (Salix Pharmaceutical) is also projected to support the

growth of this market segment owing to the patent exclusivity.

Antiemetic drug agents include the market estimation covering brand or generic

drugs such as Emend, Aloxi, Kytril and many others. Study for the gastrointestinal

drugs such as Enterogermina, Smecta, Imodium, and others are covered under the

anti-diarrhoea drug segment. While, Other GIT Therapeutics includes the revenue

generation of therapeutics such as Donnatal, Creon, Daikenchuto,

Linzess/Constella, and many others.

SAMPLE

27

5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022

Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022


5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022)

Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million), By Drug Category (2014 – 2022)

Drug 2014 2015 2016 2017 2018 2019 2020 2021 2022

CAGR%

(2016 –

2022)

Global

Commercialize

Drug Revenue

Global Pipeline

Drug Revenue 74.5%

Total


5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 – 2022)

Table 9. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category(2014 – 2022)

Drug

Category 2014 2015 2016 2017 2018 2019 2020 2021 2022

CAGR%

(2016 –

2022)

45.2%

26.7%

12.5%

3.6%

12.0%

2016

40.7%

38.6%

8.2%

2.4%10.1%

2022

Antacid & Anti-

Ulcerant

GIT Anti-inflamatory

Antiemetic

Agent

Anti-diarrhoea Agent

Other GIT Therapeutics

SAMPLE

28

Antacid &

Anti-Ulcerant

GIT Anti-

inflammatory

Antiemetic

Anti-

diarrhoea 642.2

Other GIT

Therapeutics

Total


5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022

Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 & 2022


7,798.4

4,619.0

2,152.0

621.2

2,080.6

6,045.6 5,729.9

1,215.8

363.0

1,505.5

Antacid & Anti-Ulcerant

GIT Anti-inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT Therapeutics

US$

mill

ion

2016 2022

SAMPLE

29

5.2 Antacid & Anti-Ulcerant

5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022)

Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022)

Regions 2014 2015 2016 2017 2018 2019 2020 2021 2022

CAGR%

(2016 –

2022)

North

America

Europe

Asia-Pacific

Rest of the

World 442.8

Total


5.3 GIT Anti-inflammatory

5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022)

Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022)

Regions 2014 2015 2016 2017 2018 2019 2020 2021 2022

CAGR%

(2016 –

2022)

North

America

Europe

Asia-Pacific

Rest of the

World

Total 3.7%


SAMPLE

32

6 Global Gastrointestinal Diseases Market, by Geography

6.1 Overview

The global gastrointestinal diseases market, by geography is categorized into North

America, Europe, Asia-Pacific, and Rest of the World. This chapter analyzed the

revenue generation by each region in terms of US$ million. The global market for

gastrointestinal diseases is majorly dominated by the developed regions of North

America and Europe which captured almost XX% share of the global market revenue

in 2016. Growth of this region is majorly attributed to the rising approval of novel

gastrointestinal therapeutics coupled with growing incidence of various

gastrointestinal diseases. Among which, North America is accounted for XX% share

of the total revenue in 2016. Approval of GIT Anti-inflammatory such as Lialda and

Entyvio helped the region to grow with steady growth rate during the forecast period.

However, increasing incidence of gastrointestinal diseases such as irritable bowel

syndrome and ulcerative colitis in Asia-Pacific and Rest of the World region drives

the growth of the market during the future period.

6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2022

Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2022


50.6%

35.9%

9.5%4.0%

2016

50.5%

36.4%

9.4%3.6%

2022North America

Europe

Asia

Rest of the World

SAMPLE

33

6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022)

Table 15. Global Gastrointestinal Diseases Market Size (US$ million), By Geography(2014 – 2022)

Geography 2014 2015 2016 2017 2018 2019 2020 2021 2022

CAGR%

(2016 –

2022)

North

America

Europe

Asia-Pacific

Rest of the

World 761.1

Total


6.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022

Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022


8,745.8

6,205.5

1,635.2

684.8

7,511.1

5,411.3

1,401.6

535.7

North America Europe Asia Rest of the World

US$

mill

ion

2016 2022

SAMPLE

34

6.2 North America

North America recorded US$ XX million revenue, around 50.64% share of the global

gastrointestinal diseases market. Gastrointestinal diseases market in North America

is majorly supported by the favorable government initiatives to introduce novel GIT

therapeutics. For example, in May 2014, U.S. FDA approved Takeda

Pharmaceuticals’ GIT Anti-inflammatory therapeutic, Entyvio. The drug is indicated

for the treatment of severe ulcerative colitis and moderate to severe Crohn‘s

disease. Takeda Pharmaceutical is projecting high sales growth of this integrin

receptor antagonist in the U.S. market owing to its proven safety and efficacy in

clinical trials for the treatment of ulcerative colitis and Crohn‘s disease. Additionally,

in November 2013, the U.S. Centers for Disease Control and Prevention estimated

that more than 21 million people in the U.S. get infected with noro-virus and develop

acute gastroenteritis each year which further stimulated the demand for GIT

therapeutics. However, patent expiry of blockbuster gastrointestinal therapeutics

such as Nexium, Pariet/Aciphex and many others adversely affected the growth of

the market.

6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022

Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022


87.1%

12.9%

2016

84.1%

15.9%

2022

U.S.

Canada

SAMPLE

46

7 Competitive Landscape

7.1 Market Share Analysis

Figure 18. Market Share Analysis of Key Players

Source: Annual Reports, Press Releases & Scalar Market Research analysis

7.2 Key Innovators

7.2.1 RedHill

RedHill is an emerging biopharmaceutical company, primarily focused on

commercialize and development of molecules for the treatment of gastrointestinal

and inflammatory diseases. This company is considered as one of the growing

company owing to the impressive late-stage clinical pipeline drugs for

gastrointestinal diseases. The company investigates gastrointestinal therapeutics

namely Bekinda, RHB-105 and RHB-104 under the phase - 3 clinical study which is

expected to hit the market in between 2018 - 2019. Among which, Bekinda contains

Ondansetron drug, filed for the antiemetic indication. The drug is primarily used to

prevent radiation-induced nausea and vomiting. Additionally, the company has

initiated a Phase - 2 clinical study with Bekinda for the treatment of Irritable bowel

syndrome with diarrhoea. Furthermore, the company is also investigating

therapeutics for the treatment of H. pylori infection (RHB-105) and Crohn’s disease

(RHB-104). Thus, it looks that the company have very interesting market potential to

8.3%

15.0%

12.6%

3.6%

5.0%

55.4%

Market Share (Value %), 2015 Allergan

AstraZeneca

Takeda

Pharmaceutical Company Limited

Daichi Sankyo

Eisai Co., Ltd.

Other

SAMPLE

48

8 Company Profiles

8.1 AstraZeneca

8.1.1 Overview

Table 34. AstraZeneca – Company Overview

AstraZeneca - Company Detail

Headquarters London, UK

Year of Establishment 1999

No. of Employees (2015) More than 50,000

Gastrointestinal Therapeutics Losec/Prilosec and Nexium

Revenue (2015) US$ 23,641 million

Source: Annual Reports, Investor Presentations,Primary Interviews andScalar Market Research Analysis

8.1.2 Key Strategies

8.1.2.1 Strong research and development activities

AstraZeneca is one of the key leaders for the global gastrointestinal drugs market.

The company is aggressively focusing on developing novel gastrointestinal

therapeutics for the treatment of conditions such as ulcerative colitis, irritable bowel

syndrome and Crohn’s diseases. In 2015, the company spent US$ 5,997 million for

research and development activities, up 7% as compared to the previous year. The

company aimed to develop new medicines notably in the segment of diabetes and

gastrointestinal diseases.

8.1.2.2 Novel therapeutics in company’s product offering

Owing to the strong research and development focus on gastrointestinal disease

segment, the company has developed novel therapeutics which has shown high

efficacy and safety for the treatment of GIT disorders. For example, the company

offers three gastrointestinal drugs such as Entocort (budesonide), Losec/Prilosec

(omeprazole) and Nexium (esomeprazole magnesium). These drugs are used for the

treatment and cure of GIT problems such as inflammatory bowel disease and acid

related disorders.

SAMPLE

49

8.1.3 Recent Developments

Pfizer acquired the exclusive global rights to market AstraZeneca’s Nexium

for OTC indications worldwide in 2012, and launched OTC Nexium 20mg in

the US and Europe in 2014.

In November 2015, the company entered into an agreement with Perrigo

Company plc for the divestment of US rights to Entocort, a gastroenterology

medicine for patients with mild to moderate Crohn’s disease. Under this

agreement, Perrigo acquired the right to sell Entocort capsules

SAMPLE

62

10 Appendix

10.1 Acronyms

Table 42. List of Acronyms

Acronym Expansion

IBS-D Irritable Bowel Syndrome with Diarrhea

H. pylori Helicobacter Pylori

GIT Disease Gastrointestinal Disease

U.S. FDA U.S. Food and Drug Administration

DDW Digestive Disease Week


SAMPLE

Gastrointestinal diseases market

Business

Transcript of Gastrointestinal diseases market